Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-12-10 00:00:00 ET · period of report 2021-12-08 · accession 0001708138-21-000093 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-10 | 2021-12-08 | REGN | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +2,926 | 53.9K | +6% | $0 |
| D | 2021-12-10 | 2021-12-08 | REGN | STAHL NEIL | EVP Research, Development | A - Grant | $0.00 | +12.5K | 12.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-08 | A | A | 2,926 | $0.00 | 53,883 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-12-08 | A | A | 12,494 | $0.00 | 12,494 | D | $644.54 · — to 2031-12-08 | 12,494 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |